Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forte Biosciences, Inc.TOCA · Entity 9529 | Director | October 04, 2019 | October 05, 2019 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director · President & CEO | August 24, 2026 | August 26, 2026 |
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 13, 2018 | September 18, 2018 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 04, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 7,500 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
Gossamer Bio, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Family Trust | 166 |
Reported balance
After 2026-08-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-24 · Grant · Acquired 166 · Balance 166 F1: Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations. F2: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1 non-voting convertible preferred stock. Following the Issuer's receipt of Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2036-08-23 | Direct | 5,800,051 |
Reported balance
After 2026-08-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-24 · Grant · Acquired 5,800,051 · Balance 5,800,051 F3: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations.
F2: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1 non-voting convertible preferred stock. Following the Issuer's receipt of Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of the Issuer's common stock.
F3: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
IMMUNIC, INC.
Report date September 13, 2018 · Filed September 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,500 |
Ending reported balance
After 2018-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-09-13 · Sale · Disposed 59,200 · Balance 122,743 Row 2 · 2018-09-13 · Sale · Disposed 118,243 · Balance 4,500 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 3,500 |
Reported balance
Holding disclosure · report date 2018-09-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,500 |
Kura Oncology, Inc.
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03 | Direct | 35,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-01-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-23 · Disposition to issuer · Disposed 8,717 · Balance 16,035 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 6,333 · Balance 9,702 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 9,702 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2027-04-30 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 35,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 10,716 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $49.20 · Expires 2028-07-10 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Nuvation Bio Inc.
Report date February 10, 2021 · Filed February 27, 2021
Section 16 reporting ended · disclosed 2021-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 55,000 |
Ending reported balance
After 2021-02-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-10 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Row 2 · 2021-02-10 · Grant · Acquired 30,000 · Balance 55,000 F2: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-10 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.
F2: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2023 Filed Mar 22, 2023 21:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 269,389 | $1.20 | $322,323.94 |
DisclosureSEC source: 0001728117-23-000018 · wf-form4_167951967938039.xml · nonDerivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 4,055,397 F2 · price: This transaction was executed in multiple trades at prices ranging from $1.155 to $1.21 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 21:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 544,500 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001728117-23-000018 · wf-form4_167951967938039.xml · derivative · entry 5 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,500 Underlying: Common Stock · 544,500 shares Expires 2033-03-19 F4 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 21:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 168,683 | $1.03 | $174,485.70 |
DisclosureSEC source: 0001728117-23-000018 · wf-form4_167951967938039.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 3,786,008 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.97 to 1.09 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 10,716 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001046 · marketforms-58255.xml · derivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,716 Underlying: Common Stock · 10,716 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 6,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001046 · marketforms-58255.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,050 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 544,500 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001728117-22-000104 · wf-form4_167062400607119.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,500 Underlying: Common Stock · 544,500 shares Expires 2032-12-06 F1 · derivative.exercise_date: One-third of the total number of shares subject to the option will vest on December 7, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 20:21 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 138,696 | $7.21 | $999,998.16 |
DisclosureSEC source: 0001728117-22-000059 · wf-form4_165791646217786.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 3,617,325 F1 · kind: The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 19,035 shares, with the Reporting Person's sale of 19,035 shares of common stock at a price of $8.915 per share on March 23, 2022. The Reporting Person paid to the Issuer $32,454.68, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:44 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0001209191-22-038913 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 20:55 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 19,035 | $8.92 | $169,697.03 |
DisclosureSEC source: 0001728117-22-000031 · wf-form4_164815532088964.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,465 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 01:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 5,243 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000854 · marketforms-55085.xml · derivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,243 Underlying: Common Stock · 5,243 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 01:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 3,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000854 · marketforms-55085.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,717 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:03 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001728117-22-000002 · wf-form4_164184855665829.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2032-01-05 F1 · derivative.exercise_date: One-third of the total number of shares subject to the option will vest on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:15 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001209191-21-042779 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:40 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001728117-21-000027 · wf-form4_161464558623631.xml · derivative · entry 3 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:40 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 162,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000027 · wf-form4_161464558623631.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:00 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass B Common Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012230 · ownership.xml · derivative · entry 3 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:00 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 30,000 | $10.00 | $300,000.00 |
DisclosureSEC source: 0001213900-21-012230 · ownership.xml · nonDerivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F2 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:00 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012230 · ownership.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:14 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 3,064 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000674 · marketforms-50983.xml · derivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,064 Underlying: Common Stock · 3,064 shares Expires 2031-01-14 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:14 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000674 · marketforms-50983.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,098 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| October 14, 2020 Filed Oct 14, 2020 23:28 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 96,520 | $10.36 | $999,995.46 |
DisclosureSEC source: 0001209191-20-054841 · doc4.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 3,478,629 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.55 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request. F2 · balance_after: Includes 1,491,103 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001209191-20-039068 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:51 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037633 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 01:29 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $113.20 | $0.00 |
DisclosureSEC source: 0001214659-20-000195 · marketforms-47233.xml · derivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2030-01-02 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 01:29 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000195 · marketforms-47233.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:22 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052615 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| September 27, 2019 Filed Sep 27, 2019 14:41 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 10,000 | $16.80 | $167,980.00 |
DisclosureSEC source: 0001209191-19-050928 · doc4.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 3,382,109 F1 · price: This transaction was executed in multiple trades at prices ranging from $16.25 to $17.47 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request. F2 · balance_after: Includes 2,209,015 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 13,000 | $0.00 Strike: $19.55 | $0.00 |
DisclosureSEC source: 0001209191-19-039241 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:11 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 250 | $5.15 | $1,287.38 |
DisclosureSEC source: 0001209191-19-033882 · doc4.xml · nonDerivative · entry 3 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 245,857 Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:11 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 3,890 | $5.30 | $20,613.11 |
DisclosureSEC source: 0001209191-19-033882 · doc4.xml · nonDerivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 245,607 F2 · price: The weighted average purchase price for the transaction reported was $5.2990, and the range of prices were between $5.29 and $5.30. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:11 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 38,860 | $4.59 | $178,414.03 |
DisclosureSEC source: 0001209191-19-033882 · doc4.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 241,717 F1 · price: The weighted average purchase price for the transaction reported was $4.5912, and the range of prices were between $4.22 and $5.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:20 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033652 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 22:35 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 43,500 | $0.00 Strike: $22.10 | $0.00 |
DisclosureSEC source: 0001209191-19-021358 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Common Stock · 43,500 shares Expires 2029-03-25 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 25, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:05 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $72.62 | $0.00 |
DisclosureSEC source: 0001214659-19-001392 · marketforms-44143.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2029-02-14 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 22:25 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | ConversionSeries B Preferred Stock · Derivative | 77,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-009410 · doc4.xml · derivative · entry 3 Hasnain Faheem · CIK 0001352620 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 0 Underlying: Common Stock · 17,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F1 · price: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 22:25 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | ConversionSeries A Preferred Stock · Derivative | 185,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-009410 · doc4.xml · derivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 0 Underlying: Common Stock · 41,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F1 · price: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 22:25 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | ConversionCommon Stock | 58,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-009410 · doc4.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 3,372,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date. F2 · balance_after: Includes 2,595,584 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. The shares are also subject to certain accelerated vesting provisions as set forth in more detail in the employment agreement between the Issuer and the Reporting Person. Read SEC document |
| September 13, 2018 Filed Sep 18, 2018 01:26 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 118,243 | $0.44 | $51,766.79 |
DisclosureSEC source: 0001280776-18-000088 · wf-form4_153723394976637.xml · nonDerivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| September 13, 2018 Filed Sep 18, 2018 01:26 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 59,200 | $0.44 | $25,911.84 |
DisclosureSEC source: 0001280776-18-000088 · wf-form4_153723394976637.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,743 Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:43 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039408 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 13,000 | $0.00 Strike: $16.35 | $0.00 |
DisclosureSEC source: 0001209191-18-036659 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:09 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 41,353 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001280776-18-000045 · wf-form4_152727896677922.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,353 Underlying: Common Stock · 41,353 shares Expires 2028-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:19 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 59,200 | $4.19 | $247,870.40 |
DisclosureSEC source: 0001280776-17-000092 · wf-form4_150550674325248.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,943 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.925 to $4.45. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 20:10 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 15,222 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001280776-17-000084 · wf-form4_150472861787568.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,222 Underlying: Common Stock · 15,222 shares Expires 2027-09-04 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from September 5, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:50 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001209191-17-039258 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 23, 2017 Filed May 25, 2017 21:34 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 45,022 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-17-000049 · wf-form4_149574806715383.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,022 Underlying: Common Stock · 45,022 shares Expires 2027-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:28 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-17-027904 · doc4.xml · nonDerivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 202,857 F2 · kind: The shares were purchased at the Issuer's initial public offering. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:28 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | OtherCommon Stock | 102,857 | $10.00 | $1,028,570.00 |
DisclosureSEC source: 0001209191-17-027904 · doc4.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 102,857 F1 · kind: Represents the conversion of an outstanding convertible promissory note in the principal amount of $1,000,000, plus $28,575.34 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $10.00 per share. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 01:02 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 10,869 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026752 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,869 Underlying: Common Stock · 10,869 shares Expires 2027-04-11 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.